Clinical Trials Browser

Phase 2 × Thrombocytosis × itacitinib × Clear all

NCT04629508 2025-09-02

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

Phase 2 Completed

4 enrolled 10 charts

Myeloproliferative Disorders, Polycythemia Vera, Thrombocytosis, Primary Myelofibrosis